MX2016004754A - Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados. - Google Patents

Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados.

Info

Publication number
MX2016004754A
MX2016004754A MX2016004754A MX2016004754A MX2016004754A MX 2016004754 A MX2016004754 A MX 2016004754A MX 2016004754 A MX2016004754 A MX 2016004754A MX 2016004754 A MX2016004754 A MX 2016004754A MX 2016004754 A MX2016004754 A MX 2016004754A
Authority
MX
Mexico
Prior art keywords
ctl
epithopes
lymphocyt
cytotoxic
linked
Prior art date
Application number
MX2016004754A
Other languages
English (en)
Other versions
MX377050B (es
Inventor
Satoshi Fukaya
Toshihiro Osada
Hiroshi Wada
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2016004754A publication Critical patent/MX2016004754A/es
Publication of MX377050B publication Critical patent/MX377050B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Esta invención proporciona un péptido antigénico del cáncer que se puede administrar a una amplia variedad de pacientes de cáncer en la forma de una vacuna de péptido para el cáncer sin necesidad de tipificación de HLA e independientemente de los tipos de HLA de los pacientes. Tal péptido que tiene cuatro epítopos de CTL enlazados se obtiene al enlazar cuatro péptidos de epítopos de CTL seleccionados de entre péptidos de epítopos de CTL derivados de moléculas de antígenos tumorales que se reportan como teniendo la capacidad de inducción de CTL por medio de enlazadores.
MX2016004754A 2013-10-21 2014-10-20 Nuevo péptido que tiene cuatro epítopos de linfocitos t citotóxicos (ctl) enlazados. MX377050B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013218524 2013-10-21
JP2014155132 2014-07-30
PCT/JP2014/077807 WO2015060235A1 (ja) 2013-10-21 2014-10-20 新規ｃｔｌエピトープ４連結ペプチド

Publications (2)

Publication Number Publication Date
MX2016004754A true MX2016004754A (es) 2016-07-22
MX377050B MX377050B (es) 2025-03-07

Family

ID=52992831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004754A MX377050B (es) 2013-10-21 2014-10-20 Nuevo péptido que tiene cuatro epítopos de linfocitos t citotóxicos (ctl) enlazados.

Country Status (19)

Country Link
US (1) US10137183B2 (es)
EP (1) EP3061771B1 (es)
JP (2) JP6211093B2 (es)
KR (1) KR101913333B1 (es)
CN (1) CN105658673B (es)
AU (1) AU2014337643B2 (es)
CA (1) CA2927817C (es)
DK (1) DK3061771T3 (es)
ES (1) ES2796301T3 (es)
HU (1) HUE050164T2 (es)
MX (1) MX377050B (es)
MY (1) MY179119A (es)
PH (1) PH12016500742B1 (es)
PL (1) PL3061771T3 (es)
PT (1) PT3061771T (es)
RU (1) RU2636549C1 (es)
SG (1) SG11201603165TA (es)
TW (1) TWI651094B (es)
WO (1) WO2015060235A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
EP3744847A4 (en) * 2018-01-22 2021-12-08 Japan as Represented by The Director-General of National Institute of Infectious Diseases SELECTIVE CD8 POSITIVE T CELL INDUCING VACCINE ANTIGEN
TWI805792B (zh) * 2018-06-29 2023-06-21 日商大鵬藥品工業股份有限公司 抗腫瘤劑及其評估方法
US20210401745A1 (en) * 2018-11-02 2021-12-30 Taiho Pharmaceutical Co., Ltd. Emulsion formulation and method for preparing the same
KR20220120627A (ko) 2019-12-26 2022-08-30 다이호야쿠힌고교 가부시키가이샤 수술 후 보조 요법제

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
DE69738962D1 (de) 1996-03-10 2008-10-16 Meiji Dairies Corp Auf peptiden basierendes immunotherapeutisches mittel gegen allergien
JP4138073B2 (ja) * 1998-05-08 2008-08-20 株式会社グリーンペプタイド ヒト癌退縮抗原タンパク質
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
AU762516B2 (en) 1998-08-28 2003-06-26 Dainippon Sumitomo Pharma Co., Ltd. Novel tumor antigen protein sart-3 and tumor antigen peptide thereof
US6667037B1 (en) 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2340357T3 (es) * 1999-08-05 2010-06-02 Green Peptide Co., Ltd. Antigeno tumoral.
WO2001029220A2 (en) 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
CA2393730A1 (en) 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
AU2000261861A1 (en) * 2000-07-28 2002-02-13 Hanmi Pharm. Co., Ltd. Gene expression system for mass production of hepatitis c viral rna-dependent rna polymerase and enzyme assay using fusion protein expressed therefrom
AU2002227498A1 (en) 2000-07-31 2002-02-13 Kyogo Itoh Tumor antigen
JP4097178B2 (ja) * 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
US20060035291A1 (en) * 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
ATE441713T1 (de) 2002-09-27 2009-09-15 Dainippon Sumitomo Pharma Co Tumorantigenprotein und dessen verwendung
AU2003280688A1 (en) * 2003-10-31 2005-05-19 Kurume University Combination therapy of peptide vaccination and estramustine treatment
JP4579581B2 (ja) 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のｈｌａ−ａ２４またはｈｌａ−ａ２結合ペプチド
EP1712620A4 (en) 2004-01-23 2008-05-28 Greenpeptide Co Ltd EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE
WO2005116056A1 (ja) 2004-05-26 2005-12-08 Green Peptide Co., Ltd. 副甲状腺ホルモン関連タンパク質のhla-a24またはhla-a2結合ペプチド
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
JP2006188507A (ja) 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
WO2008007711A1 (en) * 2006-07-11 2008-01-17 Kurume University Sart3-derived peptide useful in cancer vaccine therapy for hla-a3 supertype allele-positive prostate cancer patient
JP2008145715A (ja) * 2006-12-08 2008-06-26 Fujifilm Corp ポジ型感光性組成物、パターン形成方法、及び薄膜トランジスタアレイ基板
JP4972691B2 (ja) * 2007-08-16 2012-07-11 株式会社グリーンペプタイド ＨＬＡ−Ａ３スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なＬｃｋ由来ペプチド
GB0717864D0 (en) 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
KR101294514B1 (ko) * 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
JP5706895B2 (ja) 2010-07-07 2015-04-22 株式会社グリーンペプタイド がんペプチドワクチン
JP5911098B2 (ja) 2012-04-09 2016-04-27 国立研究開発法人情報通信研究機構 翻訳装置、およびプログラム
JP2014155132A (ja) 2013-02-13 2014-08-25 Murata Mfg Co Ltd 回路基板およびその製造方法
EP2966092A4 (en) * 2013-03-08 2016-11-16 Taiho Pharmaceutical Co Ltd NOVEL PEPTIDE WITH 5 CONNECTED CTL EPITOPES

Also Published As

Publication number Publication date
AU2014337643B2 (en) 2017-07-13
US10137183B2 (en) 2018-11-27
PH12016500742A1 (en) 2016-06-20
TW201601749A (zh) 2016-01-16
EP3061771A4 (en) 2017-08-16
PH12016500742B1 (en) 2020-10-23
MX377050B (es) 2025-03-07
JP6211093B2 (ja) 2017-10-11
KR101913333B1 (ko) 2018-10-30
SG11201603165TA (en) 2016-05-30
EP3061771B1 (en) 2020-04-15
TWI651094B (zh) 2019-02-21
MY179119A (en) 2020-10-28
HUE050164T2 (hu) 2020-12-28
ES2796301T3 (es) 2020-11-26
CA2927817A1 (en) 2015-04-30
AU2014337643A1 (en) 2016-05-19
PT3061771T (pt) 2020-05-06
PL3061771T3 (pl) 2020-10-19
KR20160055922A (ko) 2016-05-18
WO2015060235A1 (ja) 2015-04-30
JP2017171678A (ja) 2017-09-28
RU2636549C1 (ru) 2017-11-23
CA2927817C (en) 2019-02-26
DK3061771T3 (da) 2020-07-13
CN105658673B (zh) 2019-07-26
JPWO2015060235A1 (ja) 2017-03-09
CN105658673A (zh) 2016-06-08
US20160235828A1 (en) 2016-08-18
BR112016008254A2 (pt) 2017-09-26
EP3061771A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
ECSP19020740A (es) Anticuerpos anti-cd27
CO2017001561A2 (es) Anticuerpos anti tigit
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
UY37456A (es) Inmunoglobulinas y sus usos
BR112016014731A2 (pt) Anticorpos anti-baff
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
MX340295B (es) Anticuerpos monoclonales anti-c-met.
HK1249048A1 (zh) 靶向afp肽/mhc复合体的构建体及其用途
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
UY35964A (es) Anticuerpos humanos para pd?1
EA201691078A1 (ru) Терапевтические пептиды
MX366180B (es) Nuevos agentes de union a ha.
EA201790239A1 (ru) Молекула-носитель для антигенов
TR201815173T4 (tr) Peptit bileşimleri.
MX375994B (es) Composicion farmaceutica que comprende particulas de plga-peg.
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MX377050B (es) Nuevo péptido que tiene cuatro epítopos de linfocitos t citotóxicos (ctl) enlazados.
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.

Legal Events

Date Code Title Description
FG Grant or registration